Form 4: Apellis Pharmaceuticals' Chief Scientific Officer Executes Stock Option and Sells Shares

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On May 8, 2024, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options to acquire 78,907 shares of common stock at a price of $4.31 per share.
• Simultaneously, Deschatelets sold a total of 78,907 shares in multiple transactions.
• These sales were executed at weighted average prices of $42.1504 (56,335 shares), $42.849 (22,472 shares), and $44.025 (100 shares).
• The transactions were conducted under a pre-arranged 10b5-1 trading plan established on December 8, 2023.
• Following these transactions, Deschatelets directly owns 1,115,983 shares of Apellis Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions by an officer under a pre-existing trading plan. There's no inherent positive or negative signal, but the market may react based on the size and frequency of such transactions.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests the insider's transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The exercise of stock options and subsequent sale of shares is a common practice among executives, especially when part of a pre-arranged trading plan.
• Companies like Regeneron, Amgen, and Biogen also see frequent Form 4 filings from their executives as they manage their equity holdings.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a key executive differently, depending on the context and the overall performance of the company.
• The use of a 10b5-1 plan can reassure stakeholders that the transactions are not based on insider information.

Key Dates